ARLZ Insider Trading Activity and SEC Form 4 Filings
ARLZ insider trading summary
No open-market insider purchases or sales of Aralez Pharmaceuticals Inc. (ARLZ) have been reported on SEC Form 4 in the past 12 months.
Latest ARLZ insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 4, 2018 | Andrew I Koven | President & Chief Business Off | Sell | $59K (156,573 @ $0.37) |
| May 14, 2018 | James Patrick Tursi | Chief Medical Officer | Sell | $5K (9,348 @ $0.52) |
| May 14, 2018 | Andrew I Koven | President & Chief Business Off | Sell | $7K (13,964 @ $0.52) |
| Mar 19, 2018 | Andrew I Koven | President & Chief Business Off | Sell | $17K (9,739 @ $1.70) |
| Mar 19, 2018 | Mark A Glickman | Chief Commercial Officer | Sell | $10K (5,725 @ $1.70) |
| Mar 19, 2018 | James Patrick Tursi | Chief Medical Officer | Sell | $10K (5,950 @ $1.70) |
| Mar 19, 2018 | Eric Trachtenberg | GC, CCO & Secretary | Sell | $6K (3,471 @ $1.70) |
| Dec 8, 2017 | Arthur S Kirsch | Director | Buy | $74K (50,000 @ $1.47) |
| Oct 2, 2017 | James Patrick Tursi | Chief Medical Officer | Sell | $25K (9,960 @ $2.50) |
| Jul 28, 2017 | Scott J Charles | Chief Financial Officer | Sell | $14K (10,804 @ $1.25) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.